Search

Your search keyword '"Ollech, Jacob E."' showing total 208 results
Start Over Author "Ollech, Jacob E."
208 results on '"Ollech, Jacob E."'

3. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis

Author

Akiyama, Shintaro, Ollech, Jacob E., Traboulsi, Cindy, Rai, Victoria, Glick, Laura R., Yi, Yangtian, Runde, Joseph, Olivas, Andrea D., Weber, Christopher R., Cohen, Russell D., Olortegui, Kinga B. Skowron, Hurst, Roger D., Umanskiy, Konstantin, Shogan, Benjamin D., Rubin, Michele A., Dalal, Sushila R., Sakuraba, Atsushi, Pekow, Joel, Chang, Eugene B., Hart, John, Hyman, Neil H., and Rubin, David T.

Published
2022
Full Text
View/download PDF

5. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

Author

Edelman-Klapper, Hadar, Zittan, Eran, Bar-Gil Shitrit, Ariella, Rabinowitz, Keren Masha, Goren, Idan, Avni-Biron, Irit, Ollech, Jacob E., Lichtenstein, Lev, Banai-Eran, Hagar, Yanai, Henit, Snir, Yifat, Pauker, Maor H., Friedenberg, Adi, Levy-Barda, Adva, Segal, Arie, Broitman, Yelena, Maoz, Eran, Ovadia, Baruch, Golan, Maya Aharoni, Shachar, Eyal, Ben-Horin, Shomron, Perets, Tsachi-Tsadok, Ben Zvi, Haim, Eliakim, Rami, Barkan, Revital, Goren, Sophy, Navon, Michal, Krugliak, Noy, Werbner, Michal, Alter, Joel, Dessau, Moshe, Gal-Tanamy, Meital, Freund, Natalia T., Cohen, Dani, and Dotan, Iris

Published
2022
Full Text
View/download PDF

6. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel

Author

Avni-Biron, Irit, Bar-Gil Shitrit, Ariella, Koslowsky, Benjamin, Levartovsky, Asaf, Kopylov, Uri, Weisshof, Roni, Aviv Cohen, Nathaniel, Maharshak, Nitsan, Hovel, David, Israeli, Eran, Naftali, Timna, Goren, Idan, Snir, Yfat, Ollech, Jacob E., Banai-Eran, Hagar, Broitman, Yelena, Sharar-Fischler, Tali, Dotan, Iris, and Yanai, Henit

Published
2022
Full Text
View/download PDF

7. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes

Author

Akiyama, Shintaro, Ollech, Jacob E., Rai, Victoria, Glick, Laura R., Yi, Yangtian, Traboulsi, Cindy, Runde, Joseph, Cohen, Russell D., Skowron, Kinga B., Hurst, Roger D., Umanskiy, Konstantin, Shogan, Benjamin D., Hyman, Neil H., Rubin, Michele A., Dalal, Sushila R., Sakuraba, Atsushi, Pekow, Joel, Chang, Eugene B., and Rubin, David T.

Published
2022
Full Text
View/download PDF

8. The Role of Small-Bowel Capsule Endoscopy in the Diagnostic Algorithm of Complicated Perianal Disease.

Author

Avni-Biron, Irit, Toth, Ervin, Ollech, Jacob E., Nemeth, Artur, Johansson, Gabriele Wurm, Schweinstein, Hagai, Margalit, Reuma Yehuda, Kopylov, Uri, Dotan, Iris, and Yanai, Henit

Subjects
CROHN'S disease, CAPSULE endoscopy, CROSS-sectional imaging, SMALL intestine, CALPROTECTIN, INTESTINAL diseases
Abstract

Introduction: Complicated perianal disease (cPD) may be the sole presentation of Crohn's disease (CD). The role of small-bowel capsule endoscopy (SBCE) in the diagnostic algorithm of cPD is unclear. We aimed to evaluate the role of SBCE as a diagnostic tool, in patients with cPD, after a negative standard workup for CD. Methods: A multicenter, retrospective, cross-sectional study, in patients with cPD, and negative standard workup for CD (ileocolonoscopy and cross-sectional imaging), who underwent SBCE for suspected CD. Demographics, biomarkers, and the Lewis Score (LS) were recorded and analyzed. An LS ≥ 135 was considered a positive SBCE for diagnosing CD. Results: Ninety-one patients were included: 65 (71.4%) males; median age: 37 (29–51) years; cPD duration: 25.1 (12.5–66.1) months. Positive SBCE: 24/91 (26.4%) patients. Fecal calprotectin (FC) positively correlated with LS (r = 0.81; p < 0.001). FC levels of 100 µg/g and 50 µg/g had a sensitivity of only 40% and 55% to rule out small-bowel CD, with a negative predictive value (NPV) of only 76% and 80%, respectively. Conclusions: SBCE contributed to CD diagnosis in a quarter of patients with cPD after a negative standard workup. FC levels correlated with the degree of inflammation defined by the LS. However, the NPV of FC was low, suggesting that SBCE should be considered for patients with cPD even after a negative standard workup. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Discordant effects of ex-vivo JAK inhibition on inflammatory responses in colonic compared to ileal mucosa

Author

Kaboub, Kawsar, primary, Abu-Taha, Hanan, additional, Arrouasse, Jessica, additional, Shaham-Barda, Efrat, additional, Wasserberg, Nir, additional, Hayman-Manzur, Lucille, additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Goren, Idan, additional, Yanai, Henit, additional, Levi, Zohar, additional, Banai-Eran, Hagar, additional, Avni-Biron, Irit, additional, Ollech, Jacob E, additional, Cohen-Kedar, Sarit, additional, Dotan, Iris, additional, and Rabinowitz, Keren M, additional

Published
2024
Full Text
View/download PDF

14. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.

Author

Ollech, Jacob E., Eran-Banai, Hagar, Goren, Idan, Fischler, Tali Sharar, Avni-Biron, Irit, Snir, Yifat, Broitman, Yelena, Cohen, Shaked, Friedenberg, Adi, Pauker, Maor H., Dotan, Iris, and Yanai, Henit

Subjects
ULCERATIVE colitis, SIGMOID colon, BIOTHERAPY, HEALING, COLITIS
Abstract

Introduction: Real-world data on tofacitinib's effectiveness is limited and mainly retrospective or registry-based. We elected to conduct a pragmatic prospective study to assess the efficacy of tofacitinib for moderate to severe ulcerative colitis (UC), aiming to evaluate the ability of intestinal ultrasound (IUS) to discriminate responders vs. non-responders in real-time. Methods: This pragmatic prospective clinical study included consecutive adult patients starting tofacitinib treatment for active moderate to severe UC. Patients were evaluated at baseline and after 8 weeks of tofacitinib (clinical, biomarker, endoscopy, and IUS). The primary outcome was clinical response defined by a decrease in the full Mayo score (fMS) of ≥3 at week 8. Next, we explored ultrasonographic parameters in the sigmoid colon as potential real-time classifiers to differentiate between responders and non-responders at week 8. Results: Overall, 30 adult patients started tofacitinib; the median age was 26.3 years (IQR 22.5-39.8), and 50% were female. Most patients (86.6%) had left-sided or extensive colitis, 96.7% had previously failed biologic therapy, and 60% (18/30) were on oral corticosteroids at the start of tofacitinib. At week 8, clinical response (a decrease in the fMS ≥ 3) and remission (fMS ≤ 2) rates were 40% (12/30) and 20% (6/30), respectively. Biomarker response (FC < 250 µg/g) and biomarker normalization (FC ≤ 100 µg/g) were achieved in 47.6% (10/21) and 38.1% (8/21) of patients, respectively. Endoscopic healing (endoscopic Mayo sub-score [EMS]≤1) was achieved in 33.3% (10/30) of patients. Sigmoid bowel wall normalization as assessed by IUS (sBWT ≤ 3) was achieved in 18.2% (4/22). The best sBWT cut-off at week 8 to accurately classify endoscopic healing vs. no healing was a sBWT of 3.6 mm (AUC of 0.952 [95% CI: 0.868-1.036], p < 0.001). Conclusion: In this real-world pragmatic prospective study, tofacitinib was an effective treatment for moderate to severe UC, and IUS at week 8 accurately discriminated treatment response from non-response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis

Author

Runde, Joseph, Erondu, Amarachi, Akiyama, Shintaro, Traboulsi, Cindy, Rai, Victoria, Glick, Laura R, Yi, Yangtian, Ollech, Jacob E, Cohen, Russell D, Skowron, Kinga B, Hurst, Roger D, Umanskiy, Konstatin, Shogan, Benjamin D, Hyman, Neil H, Rubin, Michele A, Dalal, Sushila R, Sakuraba, Atsushi, Pekow, Joel, Chang, Eugene B, and Rubin, David T

Published
2022
Full Text
View/download PDF

16. A Real-World Prospective Cohort Study of Patients With Newly Diagnosed Crohn’s Disease Treated by a Multidisciplinary Team: 1-Year Outcomes

Author

Yanai, Henit, primary, Sharar Fischler, Tali, additional, Goren, Idan, additional, Eran-Banai, Hagar, additional, Ollech, Jacob E, additional, Snir, Yifat, additional, Broitman, Yelena, additional, Barkan, Revital, additional, Pfeffer-Gik, Tamar, additional, Godny, Lihi, additional, Kutokov, Yelena, additional, Friedeberg, Adi, additional, Pauker, Maor H, additional, Rabinowitz, Keren Masha, additional, Avni-Biron, Irit, additional, and Dotan, Iris, additional

Published
2023
Full Text
View/download PDF

21. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

Author

Edelman-Klapper, Hadar, primary, Rabinowitz, Keren Masha, additional, Zittan, Eran, additional, Bar-Gil Shitrit, Ariella, additional, Goren, Idan, additional, Avni-Biron, Irit, additional, Ollech, Jacob E., additional, Lichtenstein, Lev, additional, Banai-Eran, Hagar, additional, Yanai, Henit, additional, Snir, Yifat, additional, Pauker, Maor H., additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Broitman, Yelena, additional, Ben Zvi, Haim, additional, Perets, Tsachi-Tsadok, additional, Eliakim, Rami, additional, Barkan, Revital, additional, Goren, Sophy, additional, Cohen, Dani, additional, and Dotan, Iris, additional

Published
2023
Full Text
View/download PDF

29. SARS-CoV-2 IgG Antibody Levels in Women with IBD Vaccinated during Pregnancy

Author

Avni Biron, Irit, primary, Maayan, Yair, additional, Mishael, Tali, additional, Hadar, Eran, additional, Neeman, Michal, additional, Plitman Mayo, Romina, additional, Sela, Hen Y., additional, Yagel, Simcha, additional, Goldenberg, Rosalind, additional, Ben Ya’acov, Ami, additional, Grisaru Granovsky, Sorina, additional, Ollech, Jacob E., additional, Edelman-Klapper, Hadar, additional, Rabinowitz, Keren Masha, additional, Pauker, Maor H., additional, Yanai, Henit, additional, Goren, Sophy, additional, Cohen, Dani, additional, Dotan, Iris, additional, and Bar-Gil Shitrit, Ariella, additional

Published
2022
Full Text
View/download PDF

32. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study

Author

Avni‐Biron, Irit, primary, Mishael, Tali, additional, Zittan, Eran, additional, Livne‐Margolin, Moran, additional, Zinger, Adar, additional, Tzadok, Roie, additional, Goldenberg, Rosie, additional, Kopylov, Uri, additional, Ron, Yulia, additional, Hadar, Eran, additional, Helman, Sarit, additional, Granovsky, Sorina Grisaru, additional, Ollech, Jacob E., additional, Arazi, Ayelet, additional, Farkash, Rivka, additional, Pauker, Maor H., additional, Yanai, Henit, additional, Dotan, Iris, additional, and Shitrit, Ariella Bar‐Gil, additional

Published
2022
Full Text
View/download PDF

34. Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

Author

Yanai, Henit, primary, Kagramanova, Anna, additional, Knyazev, Oleg, additional, Sabino, João, additional, Haenen, Shana, additional, Mantzaris, Gerassimos J, additional, Mountaki, Katerina, additional, Armuzzi, Alessandro, additional, Pugliese, Daniela, additional, Furfaro, Federica, additional, Fiorino, Gionata, additional, Drobne, David, additional, Kurent, Tina, additional, Yassin, Sharif, additional, Maharshak, Nitsan, additional, Castiglione, Fabiana, additional, de Sire, Roberto, additional, Nardone, Olga Maria, additional, Farkas, Klaudia, additional, Molnar, Tamas, additional, Krznaric, Zeljko, additional, Brinar, Marko, additional, Chashkova, Elena, additional, Livne Margolin, Moran, additional, Kopylov, Uri, additional, Bezzio, Cristina, additional, Bar-Gil Shitrit, Ariella, additional, Lukas, Milan, additional, Chaparro, María, additional, Truyens, Marie, additional, Nancey, Stéphane, additional, Lobaton, Triana, additional, Gisbert, Javier P, additional, Saibeni, Simone, additional, Bacsúr, Péter, additional, Bossuyt, Peter, additional, Schulberg, Julien, additional, Hoentjen, Frank, additional, Viganò, Chiara, additional, Palermo, Andrea, additional, Torres, Joana, additional, Revés, Joana, additional, Karmiris, Konstantinos, additional, Velegraki, Magdalini, additional, Savarino, Edoardo, additional, Markopoulos, Panagiotis, additional, Tsironi, Eftychia, additional, Ellul, Pierre, additional, Calviño Suárez, Cristina, additional, Weisshof, Roni, additional, Ben-Hur, Dana, additional, Naftali, Timna, additional, Eriksson, Carl, additional, Koutroubakis, Ioannis E, additional, Foteinogiannopoulou, Kalliopi, additional, Limdi, Jimmy K, additional, Liu, Eleanor, additional, Surís, Gerard, additional, Calabrese, Emma, additional, Zorzi, Francesca, additional, Filip, Rafał, additional, Ribaldone, Davide Giuseppe, additional, Snir, Yifat, additional, Goren, Idan, additional, Banai-Eran, Hagar, additional, Broytman, Yelena, additional, Amir Barak, Hadar, additional, Avni-Biron, Irit, additional, Ollech, Jacob E, additional, Dotan, Iris, additional, and Aharoni Golan, Maya, additional

Published
2022
Full Text
View/download PDF

37. 9 MECHANISTIC IMPLICATIONS OF THE MEDITERRANEAN DIET IN PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE- MULTI-OMIC ANALYSIS OF A PROSPECTIVE COHORT

Author

Godny, Lihi, Elial-Fatal, Sarine, Arrouasse, Jessica, Reshef, Leah, Fischler, Tali Sharar, Kutukov, Yelena, Cohen, Shaked, Pfeffer-Gik, Tamar, Barken, Revital, Shakhman, Shelly R., Friedenberg, Adi, Pauker, Maor H., Rabinowitz, Keren M., Barda, Efrat Shaham, Ollech, Jacob E., Biron, Irit Avni, Banai-Eran, Hagar, Broitman, Yelena, Snir, Yifat, Gophna, Uri, Yanai, Henit A., and Dotan, Iris

Published
2024
Full Text
View/download PDF

38. Su1813 EXTERNALLY VALIDATED ARTIFICIAL INTELLIGENCE EXPLAINABLE INTERACTIVE TOOL FOR PREDICTING AND COMPARING THE DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS

Author

Konikoff, Tom D., Loebl, Nadav, Yanai, Henit A., Libchik, Dror, Kopylov, Uri, Albshesh, Ahmad, Weisshof, Roni, Ghersin, Itai, Bendersky, Achinoam, Avni-Biron, Irit, Snir, Yifat, Banai, Hagar, Broitman, Yelena, Perl, Leor, Dotan, Iris, and Ollech, Jacob E.

Published
2024
Full Text
View/download PDF

39. sj-docx-1-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Author

Yanai, Henit, Ungar, Bella, Kopylov, Uri, Fischler, Tali Sharar, Biron, Irit Avni, Ollech, Jacob E., Goren, Idan, Matar, Manar, Perets, Tsachi Tsadok, Shamir, Raanan, Dotan, Iris, Amir, Shira, and Assa, Amit

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tag-10.1177_17562848211068659 for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases by Henit Yanai, Bella Ungar, Uri Kopylov, Tali Sharar Fischler, Irit Avni Biron, Jacob E. Ollech, Idan Goren, Manar Matar, Tsachi Tsadok Perets, Raanan Shamir, Iris Dotan, Shira Amir and Amit Assa in Therapeutic Advances in Gastroenterology

Published
2022
Full Text
View/download PDF

40. sj-docx-2-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Author

Yanai, Henit, Ungar, Bella, Kopylov, Uri, Fischler, Tali Sharar, Biron, Irit Avni, Ollech, Jacob E., Goren, Idan, Matar, Manar, Perets, Tsachi Tsadok, Shamir, Raanan, Dotan, Iris, Amir, Shira, and Assa, Amit

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tag-10.1177_17562848211068659 for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases by Henit Yanai, Bella Ungar, Uri Kopylov, Tali Sharar Fischler, Irit Avni Biron, Jacob E. Ollech, Idan Goren, Manar Matar, Tsachi Tsadok Perets, Raanan Shamir, Iris Dotan, Shira Amir and Amit Assa in Therapeutic Advances in Gastroenterology

Published
2022
Full Text
View/download PDF

41. The Effect of Pulmonary Hypertension on Aerobic Exercise Capacity in Lung Transplant Candidates with Advanced Emphysema

Author

Adir, Yochai, Ollech, Jacob E., Vainshelboim, Baruch, Shostak, Yael, Laor, Arie, and Kramer, Mordechai R.

Subjects
Pulmonary hypertension -- Research -- Risk factors -- Development and progression -- Patient outcomes, Emphysema -- Research -- Risk factors, Chronic obstructive lung disease -- Research -- Complications and side effects -- Patient outcomes, Health
Abstract

Purpose Mild pulmonary hypertension (PH) in patients with advanced COPD is common, but its effects on exercise capacity are controversial. The objective of our study was to investigate the effects of mild PH (35 > mPAP [greater than or equal to] 25 mmHg) on exercise capacity in patients with advanced emphysema, candidates for lung transplantation. Methods We retrospectively reviewed and compare the data from right heart catheterization and cardiopulmonary exercise test, performed in patients with advanced emphysema, candidate for lung transplantation. Results Twenty patients with emphysema and no PH and 24 patients with emphysema associated with mild PH included in the study. Both patient groups had severe airways obstruction with markedly reduced FEV1 (24.9 % P ± 8.9 and 25.9 % P ± 11.7, respectively), and severely reduced DLCO (35.2 % P ± 17.3 and 39.2 % P ± 15.9). Both patients group demonstrated mark reduction in maximum workload and peak VO.sub.2 together with increased ventilatory equivalent for CO.sub.2 and extremely low breathing reserve. There was no correlation between mPAP and any of the exercise measurement. Conclusions Our study suggests that exercise capacity in patients with advanced emphysema is limited by the ventilatory impairment and the presence of mild PH has no farther impact on exercise capability., Author(s): Yochai Adir[sup.1] , Jacob E. Ollech[sup.2] , Baruch Vainshelboim[sup.1] , Yael Shostak[sup.2] , Arie Laor[sup.1] , Mordechai R. Kramer[sup.2] [sup.3] Author Affiliations: (1) Pulmonary Division, Lady Davis Carmel Medical [...]

Published
2015
Full Text
View/download PDF

42. Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial.

Author

Ollech, Jacob E., Yanai, Henit, Avni-Biron, Irit, Snir, Yifat, Banai, Hagar, Barkan, Revital, Godny, Lihi, Wasserberg, Nir, White, Ian, and Dotan, Iris

Subjects
*CALPROTECTIN, *QUALITY of life, *ANTIBIOTICS, *CLINICAL trials, *QUESTIONNAIRES
Abstract

INTRODUCTION: Whether fecal calprotectin (FC) and quality of life (QoL) questionnaires reflect change in disease activity in patients with a J-pouch is unknown. METHODS: Patients with acute pouchitis were prospectively treated with a 2-week course of antibiotics. The full Pouchitis Disease Activity Index, FC, and QoL questionnaires were measured at baseline and after antibiotic therapy. RESULTS: Twenty patients were prospectively enrolled. After 2 weeks of antibiotic treatment, the Pouchitis Disease Activity Index decreased from a median of 9 to 5 (P = 0.007). FC decreased from a median of 661 ug/g to 294 ug/g (P = 0.02), and QoL questionnaires improved significantly. DISCUSSION: FC and QoL questionnaires reflect real-time changes in inflammatory pouch activity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. An Inception Cohort of Patients with Newly Diagnosed Crohn's Disease: Therapeutic Targets Achieved One Year after Diagnosis

Author

Yanai, Henit, primary, Sharar Fischler, Tali, additional, Goren, Idan, additional, Reshef, Leah, additional, Avni-Biron, Irit, additional, Eran-Banai, Hagar, additional, Ollech, Jacob E., additional, Snir, Yifat, additional, Broitman, Yelena, additional, Barkan, Revital, additional, Pfeffer Gik, Tamar, additional, Godny, Lihi, additional, Barda, Adva Levi, additional, Kutokov, Yelena, additional, Friedeberg, Adi, additional, Pauker, Maor H., additional, Rabinowitz, Keren Masha, additional, Gophna, Uri, additional, and Dotan, Iris, additional

Published
2022
Full Text
View/download PDF

44. Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Author

Yanai, Henit, primary, Ungar, Bella, additional, Kopylov, Uri, additional, Fischler, Tali Sharar, additional, Biron, Irit Avni, additional, Ollech, Jacob E., additional, Goren, Idan, additional, Matar, Manar, additional, Perets, Tsachi Tsadok, additional, Shamir, Raanan, additional, Dotan, Iris, additional, Amir, Shira, additional, and Assa, Amit, additional

Published
2022
Full Text
View/download PDF

45. S726 A Comparative Analysis of the Modified Pouchitis Disease Activity Index and the Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease

Author

Akiyama, Shintaro, primary, Cohen, Nathaniel A., additional, Ollech, Jacob E., additional, Traboulsi, Cindy, additional, Rodriguez, Tina G., additional, Rai, Victoria, additional, Glick, Laura R., additional, Yi, Yangtian, additional, Runde, Joseph, additional, Cohen, Russell D., additional, Skowron, Kinga B., additional, Hurst, Roger D., additional, Umanskiy, Konstantin, additional, Shogan, Benjamin D., additional, Hyman, Neil H., additional, Rubin, Michele A., additional, Dalal, Sushila R., additional, Sakuraba, Atsushi, additional, Pekow, Joel, additional, Chang, Eugene B., additional, and Rubin, David T., additional

Published
2021
Full Text
View/download PDF

46. Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα

Author

Edelman-Klapper, Hadar, primary, Zittan, Eran, additional, Shitrit, Ariella Bar-Gil, additional, Rabinowitz, Keren Masha, additional, Goren, Idan, additional, Avni-Biron, Irit, additional, Ollech, Jacob E., additional, Lichtenstein, Lev, additional, Banai-Eran, Hagar, additional, Yanai, Henit, additional, Snir, Yifat, additional, Pauker, Maor H., additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Segal, Arie, additional, Broitman, Yelena, additional, Maoz, Eran, additional, Ovadia, Baruch, additional, Golan, Maya Aharoni, additional, Shachar, Eyal, additional, Ben-Horin, Shomron, additional, Perets, Tsachi-Tsadok, additional, Eliakim, Rami, additional, Goren, Sophy, additional, Navon, Michal, additional, Krugliak, Noy, additional, Werbner, Michal, additional, Alter, Joel, additional, Dessau, Moshe, additional, Gal-Tanamy, Meital, additional, Freund, Natalia T., additional, Cohen, Dani, additional, and Dotan, Iris, additional

Published
2021
Full Text
View/download PDF

49. Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction

Author

Normatov, Inessa, primary, Fluxa, Daniela, additional, Wang, Jingzhou D, additional, Ollech, Jacob E, additional, Gulotta, George E, additional, Patel, Shivani, additional, Quintero, Maria A, additional, De la Torre, Bety, additional, Solis, Norma, additional, Damas, Oriana M, additional, Deshpande, Amar R, additional, Kerman, David H, additional, Abreu, Maria T, additional, and Rubin, David T, additional

Published
2021
Full Text
View/download PDF

50. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases.

Author

Rabinowitz, Keren Masha, Navon, Michal, Edelman-Klapper, Hadar, Zittan, Eran, Bar-Gil Shitrit, Ariella, Goren, Idan, Avni-Biron, Irit, Ollech, Jacob E., Lichtenstein, Lev, Banai-Eran, Hagar, Yanai, Henit, Snir, Yifat, Pauker, Maor H., Friedenberg, Adi, Levy-Barda, Adva, Segal, Arie, Broitman, Yelena, Maoz, Eran, Ovadia, Baruch, and Aharoni Golan, Maya

Subjects
INFLAMMATORY bowel diseases, COVID-19 vaccines, IMMUNE response, BOOSTER vaccines, B cells
Abstract

Patients with inflammatory bowel disease (IBD) treated with anti-tumor-necrosis factor-alpha (TNFα) exhibited lower serologic responses one-month following the second dose of the COVID-19 BNT162b2 vaccine compared to those not treated with anti-TNFα (non-anti-TNFα) or to healthy controls (HCs). We comprehensively analyzed long-term humoral responses, including anti-spike (S) antibodies, serum inhibition, neutralization, cross-reactivity and circulating B cell six months post BNT162b2, in patients with IBD stratified by therapy compared to HCs. Subjects enrolled in a prospective, controlled, multi-center Israeli study received two BNT162b2 doses. Anti-S levels, functional activity, specific B cells, antigen cross-reactivity, anti-nucleocapsid levels, adverse events and IBD disease score were detected longitudinally. In total, 240 subjects, 151 with IBD (94 not treated with anti-TNFα and 57 treated with anti-TNFα) and 89 HCs participated. Six months after vaccination, patients with IBD treated with anti-TNFα had significantly impaired BNT162b2 responses, specifically, more seronegativity, decreased specific circulating B cells and cross-reactivity compared to patients untreated with anti-TNFα. Importantly, all seronegative subjects were patients with IBD; of those, >90% were treated with anti-TNFα. Finally, IBD activity was unaffected by BNT162b2. Altogether these data support the earlier booster dose administration in these patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results